Treatment Practice and Analysis under the Collaboration between Doctors and Pharmacists in Patient with Diffuse Large B-Cell Lymphoma Complicated by Severe Renal Insufficiency

doi:10.12114/j.issn.1007-9572.2025.0061

Chinese General Practice ›› 2026, Vol. 29 ›› Issue (12): 1599-1606.DOI: 10.12114/j.issn.1007-9572.2025.0061

• Article • Previous Articles Next Articles

Treatment Practice and Analysis under the Collaboration between Doctors and Pharmacists in Patient with Diffuse Large B-Cell Lymphoma Complicated by Severe Renal Insufficiency

1. Department of Pharmacy, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China
2. National Clinical Research Center for Cancer/Tianjin's Clinical Research Center for Cancer/Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education/Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
3. Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China
4. Department of Medical Affairs, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China

Received:2025-02-17 Revised:2025-04-28 Published:2026-04-20 Online:2026-03-12
Contact: ZHANG Jie

医药联合在弥漫大B细胞淋巴瘤合并急性肾功能衰竭患者中的治疗实践与分析

1．300060　天津市，天津医科大学肿瘤医院药学部
2．300060　天津市，国家恶性肿瘤临床医学研究中心　天津市恶性肿瘤临床医学研究中心　乳腺癌防治教育部重点实验室/天津市肿瘤防治重点实验室
3．300060　天津市，天津医科大学肿瘤医院淋巴瘤内科
4．300060　天津市，天津医科大学肿瘤医院医务处

通讯作者: 张洁
作者简介:
作者贡献：
刘婧琳负责收集资料、撰写论文；李维、张晓龙进行论文的修订；宋晓坤负责文章的质量控制与审查；周西蓓、王冠元进行数据的整理；张洁对文章整体负责，监督管理。
基金资助:
天津市医学重点学科建设资助(TJYXZDXK-3-003A); 天津医科大学肿瘤医院"十四五"高峰学科支持计划项目-突出潜力学科，淋巴瘤学科(7-2-11); 国家卫生健康委医院管理研究所医院药学高质量发展研究项目(NIHAYSZX2562); 天津医科大学2025年度医院管理创新研究项目(2025YG48); 天津医科大学肿瘤医院科研项目药学、检验、影像专项基金(Y2205)

Abstract

Abstract:

Background

The main treatment for diffuse large B-cell lymphoma is immunochemotherapy. However, the transport of most chemotherapy drugs in the body relies on the participation of the kidneys. For patients with diffuse large B-cell lymphoma, the coexistence of severe renal insufficiency undoubtedly poses a significant challenge to treatment. During the treatment process, doctors and pharmacists need to closely cooperate to maximize the therapeutic benefits for patients while ensuring their safety.

Objective

To explore the treatment service model for patients with diffuse large B-cell lymphoma complicated by acute renal failure, so as to establish effective preventive and treatment measures.

Methods

Taking the clinical data of a patient with diffuse large B-cell lymphoma complicated with severe renal insufficiency who received polatuzumab vedotin combined with chemotherapy as an example. Explore the etiology, prognostic assessment, treatment feasibility, risk assessment and management of tumor lysis syndrome, adjustment of treatment regimens, key points of pharmaceutical care analysis and determination of dialysis timing, etc.

Results

The patient's treatment process was stable, and no tumor lysis syndrome occurred. After 2 cycles of treatment, the symptoms of tumor compression were relieved, acute renal failure was effectively alleviated, and the lactate dehydrogenase level tended to be normal.

Conclusion

There are significant individual differences among patients with diffuse large B-cell lymphoma complicated by renal failure. The clinical treatment regimens should be individualized based on clear examinations and comprehensive assessments. Doctors and pharmacists should strengthen communication to ensure the safety and effectiveness of treatment.

Key words: Diffuse large B-cell lymphoma, Acute renal failure, Treatment adjustment, Dialysis, Tumor lysis syndrome

摘要：

背景

弥漫大B细胞淋巴瘤的主要治疗方式是免疫化疗。而大多数化疗药物在体内的转运依赖于肾脏的参与。对于弥漫大B细胞淋巴瘤患者而言，合并重度肾功能不全无疑给治疗带来了极大的挑战。治疗过程中，需要医生和药师密切配合，在保障患者安全的前提下，最大程度提升患者的治疗获益。

目的

本文探讨了医药联合在弥漫大B细胞淋巴瘤（DLBCL）合并急性肾功能衰竭患者治疗中的服务模式，旨在建立有效的防治措施。

方法

以1例晚期弥漫大B细胞淋巴瘤合并急性肾功能衰竭患者使用维泊妥珠单抗联合免疫化疗临床资料为例，探讨病因、预后评估、治疗可行性、肿瘤溶解综合征风险评估管理、治疗方案的调整、药学监护要点分析、透析时机的把握等。

结果

患者治疗过程平稳，未发生肿瘤溶解综合征，经过2周期治疗后，肿瘤压迫症状减轻，肾功能损伤得到有效缓解，乳酸脱氢酶水平趋于正常。

结论

弥漫大B细胞淋巴瘤合并肾功能不全患者的个体差异较大，临床治疗方案应在明确检查、全面评估的基础上进行个体化治疗。医生与药师应加强沟通，保障治疗安全有效。

关键词: 弥漫大B细胞淋巴瘤, 急性肾功能衰竭, 剂量调整, 透析, 肿瘤溶解综合征

LIU Jinglin,LI Wei,ZHANG Xiaolong, et al. Treatment Practice and Analysis under the Collaboration between Doctors and Pharmacists in Patient with Diffuse Large B-Cell Lymphoma Complicated by Severe Renal Insufficiency[J]. Chinese General Practice, 2026, 29(12): 1599-1606. DOI: 10.12114/j.issn.1007-9572.2025.0061.
刘婧琳,李维,张晓龙等. 医药联合在弥漫大B细胞淋巴瘤合并急性肾功能衰竭患者中的治疗实践与分析[J]. 中国全科医学, 2026, 29(12): 1599-1606. DOI: 10.12114/j.issn.1007-9572.2025.0061.

Figures/Tables 10

References 28

[1]	中华人民共和国国家卫生健康委员会. 弥漫大B细胞淋巴瘤诊疗指南(2022版)[A/OL]. (2022-03-29)[2025-04-25].
[2]	PERISSINOTTI A J, BISHOP M R, BUBALO J, et al. Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: results of a modified Delphi panel[J]. Cancer Treat Rev, 2023, 120: 102603. DOI: 10.1016/j.ctrv.2023.102603.
[3]	中华医学会临床药学分会, 张健, 陈思宇, 等. 肿瘤合并慢性肾脏病患者抗肿瘤治疗药物用药指导中国专家共识(2024版)[J]. 中华肿瘤杂志, 2024, 46(6): 502-516. DOI: 10.3760/cma.j.cn112152-20231110-00304.
[4]	李国辉. 抗肿瘤药物处方审核指南[M]. 北京: 人民卫生出版社, 2023: 185-189.
[5]	姜文奇, 王华庆, 高子芬, 等. 淋巴瘤诊疗学[M]. 北京: 人民卫生出版社, 2017: 413-424.
[6]	PERRY A M, ALVARADO-BERNAL Y, LAURINI J A, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab[J]. Br J Haematol, 2014, 165(3): 382-391. DOI: 10.1111/bjh.12763.
[7]	黄浦, 陈舒, 杨鑫, 等. P53及BCL2蛋白在双表达弥漫大B细胞淋巴瘤中的预后判断价值[J]. 中华血液学杂志, 2019, 40(7): 589-593. DOI: 10.3760/cma.j.issn.0253-2727.2019.07.010.
[8]	中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)淋巴瘤诊疗指南-2024[M]. 北京: 人民卫生出版社, 2024: 27-32.
[9]	CAIRO M S, COIFFIER B, REITER A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus[J]. Br J Haematol, 2010, 149(4): 578-586. DOI: 10.1111/j.1365-2141.2010.08143.x.
[10]	孟伟康. 利妥昔单抗联合苯达莫司汀致严重过敏样反应伴肿瘤溶解综合征1例[J]. 药物流行病学杂志, 2022, 1(12): 856-858. DOI: 10.19960/j.cnki.issn1005-0698.2022.12.015.
[11]	DIAO S, NICHOLS E D, DINARDO C, et al. Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax[J]. Am J Hematol, 2021, 96(3): E65-E68. DOI: 10.1002/ajh.26060.
[12]	DINARDO C D, JONAS B A, PULLARKAT V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia[J]. N Engl J Med, 2020, 383(7): 617-629. DOI: 10.1056/NEJMoa2012971.
[13]	KAROL S E, ALEXANDER T B, BUDHRAJA A, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study[J]. Lancet Oncol, 2020, 21(4): 551-560. DOI: 10.1016/S1470-2045(20)30060-7.
[14]	PELCOVITS A, MOORE J, BAKOW B, et al. Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia[J]. Support Care Cancer, 2021, 29(9): 5323-5327. DOI: 10.1007/s00520-021-06119-7.
[15]	DÖRDELMANN M, REITER A, BORKHARDT A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia[J]. Blood, 1999, 94(4): 1209-1217.
[16]	OZDEMIR M A, KARAKUKCU M, PATIROGLU T, et al. Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia[J]. Acta Haematol, 2009, 121(1): 56-62. DOI: 10.1159/000210392.
[17]	VELENOSI T J, URQUHART B L. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis[J]. Expert Opin Drug Metab Toxicol, 2014, 10(8): 1131-1143. DOI: 10.1517/17425255.2014.931371.
[18]	CELESTIN M N, MUSTEATA F M. Impact of changes in free concentrations and drug-protein binding on drug dosing regimens in special populations and disease states[J]. J Pharm Sci, 2021, 110(10): 3331-3344. DOI: 10.1016/j.xphs.2021.05.018.
[19]	LEA-HENRY T N, CARLAND J E, STOCKER S L, et al. Clinical pharmacokinetics in kidney disease: fundamental principles[J]. Clin J Am Soc Nephrol, 2018, 13(7): 1085-1095. DOI: 10.2215/CJN.00340118.
[20]	ASSI R, MASRI N, DALLE I A, et al. Polatuzumab vedotin: current role and future applications in the treatment of patients with diffuse large B-cell lymphoma[J]. Clin Hematol Int, 2021, 3(1): 21-26. DOI: 10.2991/chi.k.210305.001.
[21]	FDA: drug approval package: policy. Polatuzumab vedotin-PIIQ clinical pharmacology review(s)[A/OL]. (2019-07-02) [2025-02-10].
[22]	SEHN L H, HERRERA A F, FLOWERS C R, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma[J]. J Clin Oncol, 2020, 38(2): 155-165. DOI: 10.1200/JCO.19.00172.
[23]	ZHAO B T, CHEN R, O'CONNOR O A, et al. Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment[J]. Br J Clin Pharmacol, 2016, 82(3): 696-705. DOI: 10.1111/bcp.12988.
[24]	JILLELLA A P, DAINER P M, KALLAB A M, et al. Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis[J]. Am J Hematol, 2002, 71(3): 219-222. DOI: 10.1002/ajh.10213.
[25]	KAWANO N, YOKOTA-IKEDA N, KAWANO S, et al. Successful treatment of non-Hodgkin's lymphoma with rituximab and dose-adjusted CHOP therapy in a patient with concomitant end-stage renal disease requiring haemodialysis[J]. NDT Plus, 2011, 4(3): 186-189. DOI: 10.1093/ndtplus/sfr007.
[26]	JANUS N, THARIAT J, BOULANGER H, et al. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients[J]. Ann Oncol, 2010, 21(7): 1395-1403. DOI: 10.1093/annonc/mdp598.
[27]	GIUSTI D L, HAYTON W L. Dosage regimen adjustments in renal impairment[J]. Drug Intell Clin Pharm, 1973, 7(9): 382-387. DOI: 10.1177/106002807300700902.
[28]	郑茜子, 徐菱忆, 周庆庆, 等. 《抗肿瘤药物治疗期间肾损伤管理临床实践指南(2022)》解读(一):临床问题与良好实践声明[J]. 药物不良反应杂志, 2024, 26(5): 261-267. DOI: 10.3760/cma.j.cn114015-20240319-00178.

药物	2023-12-14	2023-12-15	2023-12-16	2023-12-17
利妥昔单抗	100 mg	100 mg	500 mg
维泊妥珠单抗		120 mg
长春地辛	1 mg
表柔比星			80 mg	40 mg
环磷酰胺			0.8 g
地塞米松	5 mg	5 mg	5 mg

药物	2023-12-14	2023-12-15	2023-12-16	2023-12-17
利妥昔单抗	100 mg	100 mg	500 mg
维泊妥珠单抗		120 mg
长春地辛	1 mg
表柔比星			80 mg	40 mg
环磷酰胺			0.8 g
地塞米松	5 mg	5 mg	5 mg

药物	2024-01-02	2024-01-03	2024-01-04	2024-01-05	2024-01-06	2024-01-07
利妥昔单抗	700 mg
维泊妥珠单抗		120 mg
表柔比星		120 mg
环磷酰胺		1 g
泼尼松		30 mg，2次/d	30 mg，2次/d	30 mg，2次/d	30 mg，2次/d	30 mg，2次/d

药物	2024-01-02	2024-01-03	2024-01-04	2024-01-05	2024-01-06	2024-01-07
利妥昔单抗	700 mg
维泊妥珠单抗		120 mg
表柔比星		120 mg
环磷酰胺		1 g
泼尼松		30 mg，2次/d	30 mg，2次/d	30 mg，2次/d	30 mg，2次/d	30 mg，2次/d

药物	2024-01-22	2024-01-23	2024-01-24	2024-01-25	2024-01-26	2024-01-27
利妥昔单抗	700 mg
维泊妥珠单抗		120 mg
表柔比星		120 mg
环磷酰胺		1 g
泼尼松		30 mg，2次/d	30 mg，2次/d	30 mg，2次/d	30 mg，2次/d	30 mg，2次/d

Treatment Practice and Analysis under the Collaboration between Doctors and Pharmacists in Patient with Diffuse Large B-Cell Lymphoma Complicated by Severe Renal Insufficiency

医药联合在弥漫大B细胞淋巴瘤合并急性肾功能衰竭患者中的治疗实践与分析

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 10

References 28

Related Articles 15

Recommended Articles

Metrics

Comments

作用时效	激素名称	等效剂量（mg）	抗炎强度	糖皮质激素活性	盐皮质激素活性
短效	可的松	25	0.8	0.8	0.8
	氢化可的松	20	1	1	1
中效	泼尼松	5	4	4	0.8
	甲泼尼龙	4	5	5	0.5
长效	地塞米松	0.75	25	25	0

药物名称	分子量	t_1/2（h）	消除途径	肾毒性	是否可透析清除	透析时机	剂量调整
维泊妥珠单抗	150 kDa	12	单甲基澳瑞他汀E：肝脏代谢，胆汁排泄单抗：细胞内酶降解	无	否	前后均可	轻、中度肾功能不全无需调整，肾功能衰竭患者适当减量。由1.8 mg/kg调整为1.4 mg/kg，总剂量120 mg
利妥昔单抗	145 kDa	76~108	细胞内酶降解	无	否	前后均可	无需调整
环磷酰胺	279.1 Da	7	肝脏代谢，肾脏排泄	有	是	透析后给药	按肾衰竭患者给药剂量调整方法，由750 mg/m²调整为404 mg/m²，总剂量800 mg
长春地辛	753.926 Da	0.912	肝脏代谢，胆汁排泄	无	是	透析后给药	无需调整
表柔比星	579.98 Da	30	肝脏代谢，胆汁排泄	无	是	透析后给药，因t_1/2长，距离下次透析时间应尽可能长	建议减量50%，考虑t_1/2长，透析后药量损失，适当补充药量。将标准剂量200 mg调整为120 mg
地塞米松	392.46 Da	3.0~4.5	肝脏代谢，胆汁排泄	无	是	透析后给药	无需调整

[1]	DING Zijun, ZHOU Nannan, LUO Xing, LUO Jieyu, HAO Wenjuan, ZHANG Chunjiang, JIN Xin, ZHAO Dan. Cognitive Impairment in Patients on Maintenance Hemodialysis and Its Influencing Factors: a Multicenter Cross-sectional Study [J]. Chinese General Practice, 2025, 28(23): 2885-2893.
[2]	ZHU Rongfang, JIN Jingjing, LIANG Xiangnan, QIAN Yuetong, GENG Tonghui, BAI Yaling, XU Jinsheng. Correlation between Mean Platelet Volume and Vascular Access Events in Maintenance Hemodialysis Patients [J]. Chinese General Practice, 2025, 28(15): 1855-1861.
[3]	ZHU Lu, AI Jun, LIAO Shengwu, HUANG Shuting, GONG Nirong, KONG Yaozhong, LIU Dehui, DOU Xianrui, ZHANG Guangqing. Association of Prognostic Nutritional Index with Cardiovascular Mortality in Patients with Peritoneal Dialysis: a Multicenter Retrospective Cohort Study [J]. Chinese General Practice, 2025, 28(05): 568-574.
[4]	CHEN Ruman, BAI Yafei, WANG Chunli, AN Na, XU Mingzhi, HE Jiqing, QI Yonghui, WANG Liheng, LI Hong. Combined Predictive Value of Neutrophil-to-lymphocyte Ratio and C-reactive Protein-to-albumin Ratio for All-cause Mortality Risk in Patients with Maintenance Hemodialysis: Cohort Study Followed for 5 Years [J]. Chinese General Practice, 2024, 27(35): 4397-4402.
[5]	LI Yongqi, CHEN Jing, LIU Lingling, YANG Jie, GONG Yanlin, CHU Jing. Barriers and Facilitators of Implementation of Benefit Finding Promotion Program in Maintenance Hemodialysis Patients Based on the i-PARIHS Framework [J]. Chinese General Practice, 2024, 27(33): 4155-4161.
[6]	NIU Di, CHEN Ruifang, PANG Xinxin, XIAO Mingzhi, ZHANG Junshao, ZHANG Xiaowei. Correlation between Systemic Immune-inflammation Index and Erythropoietin Hypo-responsiveness in Patients with Maintenance Hemodialysis [J]. Chinese General Practice, 2024, 27(29): 3635-3640.
[7]	LI Qiuling, TANG Wenwu, YU Yiwen, DENG Huan, YANG Xiaohua, CHEN Xiaoxia, JI Yifei. Establishment and Verification of Risk Prediction Model for Silent Brain Infarction in Maintenance Hemodialysis Patients: a Multicenter Study [J]. Chinese General Practice, 2024, 27(26): 3232-3239.
[8]	ZHANG Dongliang, MA Yingchun, REN Jianwei, WANG Lei, ZHAO Jingxin, LIN Xuya. Body Composition Analysis of the Effect of Water Load Parameters on Prognosis of Patients with Different Modes of Dialysis: a Multicenter Prospective Cohort Study [J]. Chinese General Practice, 2024, 27(21): 2586-2591.
[9]	WANG Xiaoxia, CAO Xuehua, LI Yan, XIONG Langyu, HU Wanqin, XIANG Feng, JIA Yu. Prevalence and Influencing Factors of Frailty in Maintenance Hemodialysis Patients in China: a Meta-analysis [J]. Chinese General Practice, 2024, 27(20): 2534-2544.
[10]	LI Jing, MA Leilei, WANG Guanran, JIANG Chen, XING Haitao, YANG Hongtao. Analysis of Clinical Characteristics and Influencing Factors of Gastrointestinal Dysfunction Associated with Peritoneal Dialysis in Uremia [J]. Chinese General Practice, 2024, 27(18): 2198-2204.
[11]	SU Guobin, LING Xitao, DUAN Ruolan, ZHANG La, XU Yuan, PENG Yu, HOU Haijing, LIU Xusheng, LU Fuhua. Selection of Therapeutic Drugs for COVID-19 Infection in Adults with Chronic Kidney Disease Based on Medical Evidence [J]. Chinese General Practice, 2023, 26(26): 3220-3229.
[12]	YANG Changyuan, LING Xitao, HU Xiaoxuan, ZHANG La, QIN Xindong, LIU Hui, LU Fuhua, SU Guobin. Clinical Interpretation of Physical Activity and Exercise in Peritoneal Dialysis: International Society for Peritoneal Dialysis and the Global Renal Exercise Network Practice Recommendations [J]. Chinese General Practice, 2023, 26(09): 1031-1037.
[13]	HU Chunyan, LI Yajing, GENG Tonghui, ZHANG Dongxue. Protective Effect of Far Infrared Therapy Using HITH-4 Type Apparatus and External Use of Hirudoid for Autogenous Arteriovenous Fistula in Diabetic Dialysis Patients [J]. Chinese General Practice, 2023, 26(08): 951-954.
[14]	LI Jiaqing, YANG Qing, YUAN Dunlu, HUANG Jingjing, CHANG Qing, NIE Jingwen, ZHOU Zhu, LI Qing. Effectiveness and Safety of Roxadustat for Renal Anemia in Dialysis-dependent Chronic Kidney Disease: a Meta-analysis [J]. Chinese General Practice, 2023, 26(06): 704-710.
[15]	WU Xiuling, LI Jianjun, YU Ying, XING Rong, WANG Lu, WANG Xuedong, TENG Fubin. Safety of Weekly Single versus Divided Administration of Moderate-dose Erythropoietin in the Treatment of Maintenance Hemodialysis Patients with Renal Anemia [J]. Chinese General Practice, 2023, 26(06): 711-717.